Distribution of creatine kinase in the general population: Implications for statin therapy

American Heart Journal

Volumn 154, Issue 4, 2007, Pages 655-661

  Brewster, Lizzy M ^a   Mairuhu, Gideon ^b   Sturk, August ^a   van Montfrans, Gert A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEGRO; NORMAL HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; SEX DIFFERENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; CREATINE KINASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; REFERENCE STANDARDS; REFERENCE VALUES; SURINAME;

EID: 34548784368     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.008     Document Type: Article

References (43)

1. Ferdinand K.C., Clark L.T., Watson K.E., et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 97 (2006) 229-235
2. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
4. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
5. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
6. Landray M., Baigent C., Leaper C., et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47 (2006) 385-395
7. Baigent C., Landray M., Leaper C., et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45 (2005) 473-484
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. Http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf [Accessed December 6, 2006]
9. McKenney J.M., Davidson M.H., Jacobson T.A., et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97 (2006) 89C-94C
10. British Cardiac Society, British Hypertension Society, Diabetes U.K., HEART UK, Primary Care Cardiovascular Society, and The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (2005) v1-v52
11. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
12. Henderson A.R., McQueen M.J., Patten R.L., et al. Testing for creatine kinase and creatine kinase-2 in Ontario: reference ranges and assay types. Clin Chem 38 (1992) 1365-1370
13. Rustad P., Felding P., and Lahti A. Nordic Reference Interval Project 2000. Proposal for guidelines to establish common biological reference intervals in large geographical areas for biochemical quantities measured frequently in serum and plasma. Clin Chem Lab Med 42 (2004) 783-791
14. NCCLS. How to define and determine reference intervals in the clinical laboratory; approved guideline C28-A2 (2000), NCCLS, Pennsylvania
15. Schumann G., Bonora R., Ceriotti F., et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 2. Reference procedure for the measurement of catalytic concentration of creatine kinase. Clin Chem Lab Med 40 (2002) 635-642
16. Horn P.S., and Pesce A.J. Effect of ethnicity on reference intervals. Clin Chem 48 (2002) 1802-1804
17. Harris E.K., Wong E.T., and Shaw S.T. Statistical criteria for separate reference intervals: race and gender groups in creatine kinase. Clin Chem 37 (1991) 1580-1582
18. Nicholson G.A., McLeod J.G., Morgan G., et al. Variable distributions of serum creatine kinase reference values. Relationship to exercise activity. J Neurol Sci 71 (1985) 233-245
19. In: Tietz N.W. (Ed). Clinical guide to laboratory tests. 3rd ed. (1995), W.B. Saunders, Co, Philadelphia 180-181
20. Lev E.I., Tur-Kaspa I., Ashkenazy I., et al. Distribution of serum creatine kinase activity in young healthy persons. Clin Chim Acta 279 (1999) 107-115
21. Apple F.S., Quist H.E., Doyle P.J., et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 49 (2003) 1331-1336
22. Meltzer H.Y. Factors affecting serum creatine phosphokinase levels in the general population: the role of race, activity and age. Clin Chim Acta 33 (1971) 165-172
23. Wong E.T., Cobb C., Umehara M.K., et al. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol 79 (1983) 582-586
24. Brewster L.M., Mairuhu G., Bindraban N.R., et al. Creatine kinase activity is associated with blood pressure. Circulation 114 (2006) 2034-2039
25. Qin W., Khuchua Z., Cheng J., et al. Molecular characterization of the creatine kinases and some historical perspectives. Mol Cell Biochem 184 (1998) 153-167
26. Joshi P., Islam S., Pais P., et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 297 (2007) 286-294
27. Wallimann T., Dolder M., Schlattner U., et al. Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors 8 (1998) 229-234
28. Clark J.F. The creatine kinase system in smooth muscle. Mol Cell Biochem 133 (1994) 221-232
29. Brewster L.M., Clark J.F., and van Montfrans G.A. Is greater tissue activity of creatine kinase the genetic factor increasing hypertension risk in black persons of sub-Saharan African descent?. J Hypertension 18 (2000) 1537-1544
30. Brewster LM, van Bree S, Reijneveld JC, et al. Hypertension Risk in Idiopathic HyperCKemia. J of Neurology [in press].
31. Thompson P.D., Clarkson P.M., Rosenson R.S., and The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 97 (2006) 69C-76C
32. Law M., and Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 97 (2006) 52C-60C
33. Hansen K.E., Hildebrand J.P., Ferguson E.E., et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165 (2005) 2671-2676
34. Brewster L.M., and van Montfrans G. Letter by Brewster and van Montfrans regarding article, "Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 116 (2007) e7
35. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
36. Brewster LM, Stronks K, Zwinderman AH, et al. Creatine kinase and the correlates of blood pressure in a random population sample. Hypertension [under review].
37. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 210 (2006) 94-102
38. Lane R.J., and Roses A.D. Variation of serum creatine kinase levels with age in normal females: implications for genetic counselling in Duchenne muscular dystrophy. Clin Chim Acta 113 (1981) 75-86
39. Miller W.G., Chinchilli V.M., Gruemer H.D., et al. Sampling from a skewed population distribution as exemplified by estimation of the creatine kinase upper reference limit. Clin Chem 30 (1984) 18-23
40. Swaminathan R., Ho C.S., and Donnan S.P. Body composition and plasma creatine kinase activity. Ann Clin Biochem 25 (1988) 389-391
41. Ferdinand K.C. Ethnic, gender, and age-related differences in the treatment of dyslipidemia. Am J Manag Care 12 (2006) S400-S404
42. Clark L.T., Maki K.C., Galant R., et al. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med 21 (2006) 320-326
43. Goff D.C., Bertoni A.G., Kramer H., et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis: gender, ethnicity, and coronary artery calcium. Circulation 113 (2006) 647-656